8-K VK5211 PHASE 2 RESULTS

Company

Viking Therapeutics, Inc.

Filed

November 28, 2017

Period of Report

November 28, 2017

Accession Number

0001564590-17-024262

An 8-K is a current report used to announce material events that shareholders should know about — such as earnings releases, mergers, executive changes, or bankruptcy. Learn more about 8-K filings →